- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Researchers identify potential Zika virus target
New research provides insights into why infection with Zika virus after birth generally causes only mild symptoms, whereas devastating fetal malformations can develop when infection occurs during pregnancy.
Healthy people are protected by antiviral factors of our innate immune system. Investigators have now shown that reducing levels of one antiviral factor called interferon-induced transmembrane protein 3 (IFITM3) makes cultured cells highly sensitive to Zika virus infection.
The team found that IFITM3 normally stops multiplication of the virus in human cells at an early step, preventing the infected cells from "implosive" cell death. Therefore, drugs that block this cell death pathway might be helpful for preventing the effects of Zika virus infection during pregnancy.
"We describe a striking succession of events that may lead to the death of cells infected with Zika virus. Hopefully, the cells are equipped with antiviral gatekeepers that allow the host to control the infection," said Dr. Olivier Schwartz, senior author of The EMBO Journal study.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd